Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420835 | 0.89 | LMNA (0.57) | ACLYHTR6PTGDRPTGDR2PPARG | |
| SCHEMBL6426199 | 0.87 | PTGDR2 (0.58) | ACLYHTR6PTGDRPTGDR2MAPT | |
| SCHEMBL3562004 | 0.86 | PTGDR2 (0.51) | ACLYHTR6PTGDRPTGDR2SRC | |
| SCHEMBL3563869 | 0.84 | HTR6 (0.50) | ACLYHTR6PTGDRPTGDR2SRC | |
| SCHEMBL3558278 | 0.84 | PTGDR2 (0.68) | ACLYHTR6PTGDRPTGDR2SRC | |
| SCHEMBL6773812 | 0.83 | MAPT (0.65) | ACLYHTR6PTGDRPTGDR2PPARG | |
| SCHEMBL3564084 | 0.83 | SRC (0.51) | ACLYHTR6PTGDRPTGDR2SRC | |
| SCHEMBL3563847 | 0.83 | ACLY (0.58) | ACLYHTR6SRCPPARGPPARA | |
| SCHEMBL3557075 | 0.82 | HTR6 (0.64) | HTR6PTGDRPTGDR2SRCMAPT | |
| SCHEMBL28485336 | 0.81 | HTR6 (0.48) | ACLYHTR6PTGDRPTGDR2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567492-B1 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LTD (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-7718690-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | RAMAKRISHNA VENKATA SATYA NIROGI | 2010-05-18 | — | — | US | disclosed |
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-7507835-B2 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD. (IN) | 2009-03-24 | — | — | US | disclosed |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
| CN-1720227-A | N-arylsulfonyl-3-aminoalkoxyindoles | SUVEN LIFE SCIENCES LTD (IN) | 2006-01-11 | — | — | CN | disclosed |
| EP-1567492-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | Suven Life Sciences Limited (IN) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048328-A2 | N-ARYLSULFONYL-3-AMINOALKOXYINDOLES | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131507-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | ACLY 4542/4885HTR6 56/4885PTGDR 726/4885 |
| US-20060173193-A1 | N-arylsulfonyl-3-aminoalkoxyindoles | HTR3C, HTR3A, AANAT | ACLY 4542/4885HTR6 56/4885PTGDR 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.